1. 020 Long-term efficacy of ocrelizumab in relapsing multiple sclerosis: 6 study years. Issue 6 (27th May 2022) Authors: Giovannoni, Gavin; Kappos, Ludwig; Seze, Jerome de; Hauser, Stephen L; Overell, James; Koendgen, Harold; Prajapati, Kalpesh; Manfrini, Marianna; Wang, Qing; Wolinsky, Jerry S Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 93:Issue 6(2022) Page Start: A19 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 031 Long-term efficacy of ocrelizumab in primary progressive multiple sclerosis: 6.5-study years. Issue 6 (27th May 2022) Authors: Schmierer, Klaus; Wolinsky, Jerry S; Brochet, Bruno; Hartung, Hans-Peter; Naismith, Robert; Koendgen, Harold; Manfrini, Marianna; Sauter, Annette; Prajapati, Kalpesh; Kappos, Ludwig Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 93:Issue 6(2022) Page Start: A23 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 033 Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis (PPMS) in the oratorio study (ENCORE). Issue 6 (24th May 2018) Authors: Fox, Edward; Markowitz, Clyde; Applebee, Angela; Montalban, Xavier; Wolinsky, Jerry S; Belachew, Shebeshih; Fiore, Damian; Han, Jian; Musch, Bruno; Giovannoni, Gavin Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 89:Issue 6(2018) Page Start: A14 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 034 Updated safety analysis of ocrelizumab in multiple sclerosis. Issue 6 (27th May 2022) Authors: Schmierer, Klaus; Hauser, Stephen L; Kappos, Ludwig; Montalban, Xavier; Craveiro, Licinio; Hughes, Richard; Prajapati, Kalpesh; Koendgen, Harold; Pradhan, Ashish; Wolinsky, Jerry S Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 93:Issue 6(2022) Page Start: A24 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 056 Efficacy and safety of the Bruton's tyrosine kinase inhibitor evobrutinib (M2951) in patients with relapsing multiple sclerosis over 48 weeks: a randomized, placebo-controlled, phase 2 study. (29th July 2019) Authors: Montalban, Xavier; Arnold, Douglas L; Weber, Martin S; Staikov, Ivan; Piasecka-Stryczynska, Karolina; Gillett, Alan; Martin, Emily C; Syed, Sana; Dangond, Fernando; Wolinsky, Jerry S Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 90(2019)e7 Page Start: A18 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 061 Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis (RMS) (ENCORE). Issue 6 (24th May 2018) Authors: Kappos, Ludwig; Wolinsky, Jerry S; Giovannoni, Gavin; Arnold, Douglas L; Lublin, Fred; Wang, Qing; Model, Fabian; Wei, Wei; Garren, Hideki; Manfrini, Marianna; Belachew, Shibeshih; Hauser, Stephen Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 89:Issue 6(2018) Page Start: A25 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 068 Evaluation of the long-term treatment effect of teriflunomide on cognitive outcomes and association with brain volume change: data from temso and its extension study. Issue 6 (24th May 2018) Authors: Sprenger, Till; Lechner-Scott, Jeannette; Sormani, Maria P; Wolinsky, Jerry S; Wuerfel, Jens; Thangavelu, Karthinathan; Cavalier, Steven; Mandel, Matt; Kappos, Ludwig Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 89:Issue 6(2018) Page Start: A28 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 178 Long-term efficacy of ocrelizumab in relapsing multiple sclerosis. Issue 12 (14th November 2019) Authors: Giovannoni, Gavin; Hauser, Stephen L; Brochet, Bruno; Montalban, Xavier; Naismith, Robert T; Wolinsky, Jerry S; Hubeaux, Stanislas; Mehta, Lahar; Model, Fabian; Kappos, Ludwig Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 90:Issue 12(2019) Page Start: e47 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability. Issue 1 (March 2020) Authors: Wolinsky, Jerry S; Engmann, Natalie J; Pei, Jinglan; Pradhan, Ashish; Markowitz, Clyde; Fox, Edward J Journal: Multiple sclerosis journal, experimental, translational and clinical Issue: Volume 6:Issue 1(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Baseline EDSS proportions in MS clinical trials affect the overall outcome and power: A cautionary note. (June 2017) Authors: Wang, Guoqiao; Cutter, Gary R; Cofield, Stacey S; Lublin, Fred; Wolinsky, Jerry S; Gustafson, Tarah; Krieger, Stephen; Salter, Amber Journal: Multiple sclerosis Issue: Volume 23:Number 7(2017) Page Start: 982 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗